

# BIOTECH Therapy



## NL4TB

Technology matured by



#Tuberculosis

#Antibiotic

#Antibioresistance

### Achievements

- 200 synthesized analogues → Anti-tuberculosis MIC - 10 nM
- Active on non-replicating drug tolerant tuberculosis
- Mycobacterium specific inhibitor of electron transport (image)
- No cytotoxicity

### Pharmacokinetic/ADME properties:

- $400 < \text{MW} < 550 \text{ g.mol}^{-1}$ ;  $3.5 < \text{LogD} < 5$ , High solubility
- Chemically and metabolically stable
- *In vivo*  $t_{1/2} > 6 \text{ h}$ ;  $C_{\text{max}} > 10 \text{ }\mu\text{M}$ , accumulation in lungs
- *In vivo* POC established in *M. marinum* infected zebrafish

On going

*In vivo* POC mouse model


IP status

Priority date: June 7th 2022

## Novel Narrow Spectrum Antibiotic against Mycobacteria

Tricyclic-Spirolactams (TriSLa compounds)

(*Mycobacterium tuberculosis*, *abscessus*, *avium*)



J. Med. Chem. 2022, 65, 16651–16664

CONTACT SATT Nord

Mathieu NOWARA Business Developer | mathieu.nowara@sattnord.fr



Région  
Hauts-de-France



Cofinancé par  
l'Union européenne